Zacks Investment Research
08 Oct 2026, 17:51 UTC · 1h ago
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Impact · against what's priced in
The ruling is a significant blow to Merck's strategy to hedge its 2028 patent cliff, as the blocking of Keytruda SC in eight European markets undermines its subcutaneous transition. For Halozyme, the victory is positive but only marginally so, as the current valuation already reflects strong near-term guidance and high margins, leaving limited room for immediate upside from this specific regional win.
- MRK−0.40
Challenges what's priced in
- The price assumes
A steady continuation of Keytruda's current revenue
The price assumes a steady revenue base for Keytruda, but the blocking of the subcutaneous version in eight European markets removes a key tactical hedge against the December 2028 patent cliff.
What MRK's price assumes · Sep 11
Search tags
